HONG KONG – A wave of bad news, not least of which is a faulty vaccines scandal in China, has hit Hong Kong-listed biotechnology stocks hard in 2018. However, on Oct. 31, Innovent Biologics Inc. debuted on the Hong Kong Stock Exchange with a surprising 19 percent price jump, breaking the curse of sharp price drops when the previous three biotech flotations first began trading.